In the last trading session, 1.63 million Moleculin Biotech Inc (NASDAQ:MBRX) shares changed hands as the company’s beta touched 1.94. With the company’s per share price at $1.07 changed hands at -$0.21 or -16.41% during last session, the market valuation stood at $4.45M. MBRX’s last price was a discount, traded about -867.29% off its 52-week high of $10.35. The share price had its 52-week low at $0.40, which suggests the last value was 62.62% up since then.

Moleculin Biotech Inc (NASDAQ:MBRX) trade information

Instantly MBRX was in red as seen at the end of in last trading. With action -50.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -37.06%, with the 5-day performance at -50.92% in the red. However, in the 30-day time frame, Moleculin Biotech Inc (NASDAQ:MBRX) is -39.20% down.

According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 18.25%. The 2025 estimates are for Moleculin Biotech Inc earnings to increase by 49.80%, but the outlook for the next 5-year period is at 36.38% per year.

MBRX Dividends

Moleculin Biotech Inc is expected to release its next quarterly earnings report in March.

Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund . With 42.47 shares estimated at $45440.0 under it, the former controlled 1.02% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.73% of the shares, roughly 30.31 shares worth around $32435.0.